Depodur is a drug owned by Pacira Pharmaceuticals Inc. It is protected by 9 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 31, 2017. Details of Depodur's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5891467 | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
Jan, 2017
(7 years ago) |
Expired
|
| US5962016 | Multivesicular liposomes utilizing neutral lipids to modify in vivo release |
Jan, 2017
(7 years ago) |
Expired
|
| US6171613 | Method for producing liposomes with increased percent of compound encapsulated |
Oct, 2016
(8 years ago) |
Expired
|
| US6241999 | Method for producing liposomes with increased percent of compound encapsulated |
Sep, 2016
(8 years ago) |
Expired
|
| US6193998 | Method for producing liposomes with increased percent of compound encapsulated |
Sep, 2016
(8 years ago) |
Expired
|
| US5997899 | Method for producing liposomes with increased percent of compound encapsulated |
Sep, 2016
(8 years ago) |
Expired
|
| US5807572 | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
Sep, 2015
(9 years ago) |
Expired
|
| US5931809 | Epidural administration of therapeutic compounds with sustained rate of release |
Jul, 2015
(9 years ago) |
Expired
|
| US5723147 | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
Mar, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Depodur is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Depodur's family patents as well as insights into ongoing legal events on those patents.
Depodur's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Depodur's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 31, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Depodur Generic API suppliers:
Morphine Sulfate is the generic name for the brand Depodur. 32 different companies have already filed for the generic of Depodur, with Strides Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Depodur's generic
Alternative Brands for Depodur
Depodur which is used for postoperative pain management via single-dose epidural administration at the lumbar level., has several other brand drugs using the same active ingredient (Morphine Sulfate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Alpharma Pharms |
| |
| Fresenius Kabi Usa |
| |
| King Pharms Llc |
| |
| Ohemo Life |
| |
| Zyla |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Morphine Sulfate, Depodur's active ingredient. Check the complete list of approved generic manufacturers for Depodur
About Depodur
Depodur is a drug owned by Pacira Pharmaceuticals Inc. It is used for postoperative pain management via single-dose epidural administration at the lumbar level. Depodur uses Morphine Sulfate as an active ingredient. Depodur was launched by Pacira Pharms Inc in 2004.
Approval Date:
Depodur was approved by FDA for market use on 18 May, 2004.
Active Ingredient:
Depodur uses Morphine Sulfate as the active ingredient. Check out other Drugs and Companies using Morphine Sulfate ingredient
Treatment:
Depodur is used for postoperative pain management via single-dose epidural administration at the lumbar level.
Dosage:
Depodur is available in injectable, liposomal form for epidural use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 15MG/1.5ML (10MG/ML) | INJECTABLE, LIPOSOMAL | Discontinued | EPIDURAL |
| 10MG/ML (10MG/ML) | INJECTABLE, LIPOSOMAL | Discontinued | EPIDURAL |
| 20MG/2ML (10MG/ML) | INJECTABLE, LIPOSOMAL | Discontinued | EPIDURAL |